Neurocrine Biosciences, Inc.

Good day everyone and welcome to today's NeuroKrin Biosciences Second Quarter 2025 Results Conference. At this time all participants are in a listen-only mode. Later you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing star 1 on your telephone keypad. You may withdraw yourself from the queue by pressing star 2. Please note this call may be recorded and I will be standing by if you should need any assistance. It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tuschla. Please go ahead sir.

Thank you and happy Wednesday everyone. Welcome to NeuroKrin Biosciences Second Quarter 2025 Earnings Call. With me today are Kyle Gano, Chief Executive Officer, Matt Abernathy, Chief Financial Officer, Eric Benovitch, Chief Commercial Officer, Ivy Roberts, and for one first time as Chief Medical Officer Sanjay Keswani. During today's call we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After prepared remarks we will jump into Q&A. I now turn the call over to Kyle.

Thank you Todd. Good afternoon everyone. We were especially pleased with our standout second quarter that delivered high double-digit growth, which showcased our diversified revenue profile and highlighted the organization's ongoing evolution. From a commercial perspective our Ingresa-based business continues to post solid growth and we are excited by the strong early performance of Krenesiti. For Ingresa, our strategic investments to enhance payer access led to another record of new patient starts and TRX for the quarter, further strengthening our leadership in the BMET II class. We remain confident that these market access initiatives will continue to drive long-term growth for the Ingresa franchise. For Krenesiti, we once again outperform internal expectations. To date, Krenesiti has been well received by both patients and prescribers, underscoring the significant unmet needs within the classical congenital adrenal hyperplasia community. With a strong product profile across efficacy, safety, and tolerability, we believe Krenesiti is well positioned to become the standard of care for patients with classical CH and has all the attributes to be NeuroKren's second commercial blockbuster. Coming off a successful Endo conference this month, I'm reminded of how far we've come. In fact, it was back in March of 2015 at Endo that we first presented proof of concept data and CH with a CRF receptor antagonist. This year, over a decade later, I had the opportunity to meet directly with clinicians in the field, which gave me an even deeper appreciation for the impact we are making for CH patients and for the importance of the work we do every day at NeuroKren. Putting patients at the center isn't just a guiding principle, it's what drives meaningful progress. It goes without saying, we're deeply grateful to the patients, their caregivers and families, and the investigators who made this progress possible in partnership with the NeuroKren team. We look forward to our continued collaboration. Turning to the clinical pipeline, we believe we have one of the industry's deepest diversified neuroscience-focused pipelines. I would like to welcome Sanjay Keswani, who officially joined us in June as our Chief Medical Officer. He joins NeuroKren at an exciting time as we have initiated multiple phase three programs within a single calendar year with both Osev Ampator and MBA 568, Enrolling Patients in Registrational Studies. At our upcoming R&D day on December 16th, we look forward to sharing additional data from both programs as well as our perspective on the psychiatry portfolio and progress in R&D transformation. On the preclinical front, our R&D engine led by Chief Scientific Officer Jude Onya is advancing internally discovered biologics candidates towards the clinic, which further diversifies our mechanistic approach to address a broad range of diseases aligned with our expertise and strategic focus. Overall, I'm pleased with our performance in the first half of the year. Looking ahead, sustained revenue contribution from both Ingresa and now Cronesti will enable us to further invest in advancing and expanding our pipeline, and importantly, helping more patients than ever before in solidifying NeuroKren's position as a leading neurology-focused enterprise. With that, I will turn the call over to Matt.